{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:26:59Z","timestamp":1793410019376,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Gerontology and Geriatrics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.archger.2025.106065","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T07:51:30Z","timestamp":1761637890000},"page":"106065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies"],"prefix":"10.1016","volume":"141","author":[{"given":"Zhaoshuang","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-6048","authenticated-orcid":false,"given":"Shuyue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004541","article-title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: A population-based cohort study","volume":"13","author":"Abdullah","year":"2025","journal-title":"BMJ Open Diabetes Research & Care"},{"key":"10.1016\/j.archger.2025.106065_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102751","article-title":"Reducing Alzheimer's disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection","volume":"108","author":"Alami","year":"2025","journal-title":"Ageing Research Reviews"},{"issue":"4","key":"10.1016\/j.archger.2025.106065_bib0028","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"10","key":"10.1016\/j.archger.2025.106065_bib0003","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nature reviews. Endocrinology"},{"issue":"6","key":"10.1016\/j.archger.2025.106065_bib0017","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00125-021-05393-8","article-title":"Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: Results of the randomised double-blind, active-controlled CAROLINA-COGNITION study","volume":"64","author":"Biessels","year":"2021","journal-title":"Diabetologia"},{"issue":"10296","key":"10.1016\/j.archger.2025.106065_bib0009","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.archger.2025.106065_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108276","article-title":"Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study","volume":"34","author":"Chiang","year":"2025","journal-title":"Journal of Stroke and Cerebrovascular Diseases : The Official Journal of National Stroke Association"},{"issue":"2","key":"10.1016\/j.archger.2025.106065_bib0001","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"issue":"5","key":"10.1016\/j.archger.2025.106065_bib0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-127-5-199709010-00008","article-title":"Formulating questions and locating primary studies for inclusion in systematic reviews","volume":"127","author":"Counsell","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1016\/j.archger.2025.106065_bib0024","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MED.0000000000000783","article-title":"Type 2 diabetes mellitus and cognitive function: Understanding the connections","volume":"30","author":"Dao","year":"2023","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"issue":"Suppl 1","key":"10.1016\/j.archger.2025.106065_bib0010","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.archger.2025.106065_bib0038","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimer's Research & Therapy"},{"issue":"11","key":"10.1016\/j.archger.2025.106065_bib0027","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1016\/j.archger.2025.106065_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101581","article-title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study","volume":"50","author":"Hong","year":"2024","journal-title":"Diabetes Metabolism"},{"issue":"6","key":"10.1016\/j.archger.2025.106065_bib0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamapsychiatry.2015.0082","article-title":"Effect of depression and diabetes mellitus on the risk for dementia: A national population-based cohort study","volume":"72","author":"Katon","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.archger.2025.106065_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105158","article-title":"Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice","volume":"150","author":"Khan","year":"2021","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.archger.2025.106065_bib0008","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dom.15331","article-title":"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis","volume":"26","author":"Kuate Defo","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010028","article-title":"Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus Sulfonylureas: A real-world population-based cohort study","volume":"8","author":"Kim","year":"2018","journal-title":"Journal of Clinical Medicine"},{"issue":"11","key":"10.1016\/j.archger.2025.106065_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: A systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jdi.13914","article-title":"Association between diabetes mellitus and post-stroke cognitive impairment","volume":"14","author":"Lee","year":"2023","journal-title":"Journal of Diabetes Investigation"},{"issue":"1","key":"10.1016\/j.archger.2025.106065_bib0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13195-024-01645-y","article-title":"Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: A systematic review and network meta-analysis of observational studies and randomized controlled trials","volume":"16","author":"Li","year":"2024","journal-title":"Alzheimer's Research & Therapy"},{"issue":"3","key":"10.1016\/j.archger.2025.106065_bib0018","doi-asserted-by":"crossref","first-page":"E650","DOI":"10.1210\/clinem\/dgae281","article-title":"Dipeptidyl peptidase 4 inhibitors vs Metformin for new-onset dementia: A propensity score-matched cohort study","volume":"110","author":"Liu","year":"2025","journal-title":"Journal of Clinical Endocrinology Metabolism"},{"issue":"10452","key":"10.1016\/j.archger.2025.106065_bib0002","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.archger.2025.106065_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102018","article-title":"Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways","volume":"90","author":"Mancinetti","year":"2023","journal-title":"Ageing Research Reviews"},{"issue":"4","key":"10.1016\/j.archger.2025.106065_bib0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.archger.2025.106065_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: A propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"9","key":"10.1016\/j.archger.2025.106065_bib0037","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam Study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.archger.2025.106065_bib0033","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1111\/dom.15918","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks","volume":"26","author":"Pai","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3\u20134","key":"10.1016\/j.archger.2025.106065_bib0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000543533","article-title":"The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes: A meta-analysis of cohort studies","volume":"115","author":"Pan","year":"2025","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.archger.2025.106065_bib0023","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: A key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP Journal Club"},{"key":"10.1016\/j.archger.2025.106065_bib0032","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: Population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ (Clinical research ed.)"},{"issue":"3","key":"10.1016\/j.archger.2025.106065_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"23","key":"10.1016\/j.archger.2025.106065_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233767","article-title":"Development of dementia in type 2 diabetes patients: Mechanisms of insulin resistance and antidiabetic drug Development","volume":"11","author":"Singh","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.archger.2025.106065_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"European Journal of Epidemiology"},{"issue":"5","key":"10.1016\/j.archger.2025.106065_bib0039","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/alz.12437","article-title":"Nonenzymatic function of DPP4 in diabetes-associated mitochondrial dysfunction and cognitive impairment","volume":"18","author":"Sun","year":"2022","journal-title":"Alzheimer's & Dementia : The Journal of the Alzheimer's Association"},{"key":"10.1016\/j.archger.2025.106065_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: A scoping review","volume":"13","author":"Tharmaraja","year":"2022","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"2","key":"10.1016\/j.archger.2025.106065_bib0012","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: A population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.archger.2025.106065_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: A population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.archger.2025.106065_bib0029","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/dom.16239","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: A population-based cohort study","volume":"27","author":"Zhuo","year":"2025","journal-title":"Diabetes, Obesity & Metabolism"}],"container-title":["Archives of Gerontology and Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016749432500322X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016749432500322X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:30:44Z","timestamp":1778502644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016749432500322X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S016749432500322X"],"URL":"https:\/\/doi.org\/10.1016\/j.archger.2025.106065","relation":{},"ISSN":["0167-4943"],"issn-type":[{"value":"0167-4943","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies","name":"articletitle","label":"Article Title"},{"value":"Archives of Gerontology and Geriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.archger.2025.106065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106065"}}